跳到正文
原文
Endpoints News· @endpts · X·· 12 天前精选AI 评分62
AI 导读

Kamau公布其重启的Graphite Bio镰状细胞基因编辑疗法首批数据,首个队列3例患者均实现无需输血。该疗法此前由Graphite Bio开发,现由Kamau推进。

推荐理由

首队列3例患者均脱离输血,为这款重启的镰状细胞基因编辑疗法提供了早期人体数据参照。

正文

Kamau is reviving Graphite Bio's sickle cell gene editing therapy, and all three patients in its first cohort are transfusion-free. https://endpoints.news/kamau-shares-first-data-from-revamped-sickle-cell-gene-editing-therapy/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial

来源:Endpoints News · x.com